From MAFLD to hepatocellular carcinoma and everything in between

作     者：Sarah Da Won Bae Jacob George Liang Qiao Sarah Da Won Bae;Jacob George;Liang Qiao

作者机构：Storr Liver CentreWestmead Institute for Medical ResearchUniversity of Sydney and Westmead HospitalWestmeadNSW 2145Australia 

出 版 物：《Chinese Medical Journal》 (中华医学杂志（英文版）)

年 卷 期：2022年第135卷第5期

页      面：547-556页

核心收录：

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

基　　金：JG is supported by the Robert W.Storr Bequest to the Sydney Medical Foundation,University of Sydney and National Health and Medical Research Council of Australia(NHMRC)Program and Investigator Grants(AAP2008983,APP1053206,APP1196492) LQ is supported by NSW Cancer Council grants(APP1145008,APP1070076) 

主　　题：Metabolic(dysfunction)associated fatty liver disease Liver disease Liver cancer 

摘      要：Metabolic(dysfunction)associated fatty liver disease(MAFLD),previously known as non-alcoholic fatty liver disease,is the most common cause of chronic liver disease *** risk factors contribute to the pathogenesis of MAFLD with metabolic dysregulation being the final arbiter of its development and *** poses a substantial economic burden to societies,which based on current trends is expected to increase over *** studies have addressed various aspects of MAFLD from its risk associations to its economic and social burden and clinical diagnosis and management,as well as the molecular mechanisms linking MAFLD to end-stage liver disease and hepatocellular *** review summarizes current understanding of the pathogenesis of MAFLD and related diseases,particularly liver *** therapeutic agents for MAFLD and diagnostic biomarkers are discussed.